PRESCIDO
DEAD

Serial Number

97253726

Owner

NOVARTIS AG

Attorney

Maury M. Tepper, III

Filing Date

Feb 4, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PRESCIDO Trademark

Serial Number: 97253726

PRESCIDO is a trademark filed by NOVARTIS AG on February 4, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,174 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

February 4, 2022

Registration Date

Not Registered

Published for Opposition

September 27, 2022

Goods & Services

Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for diagnosing and treating gastro-intestinal diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; medical apparatus and instruments for use in hematology and in tissue and organ transplantation; medical apparatus and instruments for the diagnosis, prevention and treatment of eye diseases and conditions; medical apparatus and instruments for the diagnosis, prevention and treatment of heart rhythm disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of immune system related diseases and disorders; medical apparatus and instruments for the diagnosis, prevention and treatment of kidney diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of diabetes; medical apparatus and instruments for the diagnosis, prevention and treatment of hypertension; medical apparatus and instruments for the diagnosis, prevention and treatment of skin disorders; medical apparatus and instruments for use in urology; medical apparatus and instruments for ophthalmological use; medical apparatus and instruments for the diagnosis, prevention and treatment of cancer and tumors; medical apparatus and instruments for the diagnosis, prevention and treatment of allergies; medical apparatus and instruments for the diagnosis, prevention and treatment of bone diseases; medical apparatus and instruments for the diagnosis, prevention and treatment of respiratory diseases and asthma; radiological apparatus and instruments for medical use in the nature of radiological apparatus for medical purposes; genetic testing apparatus and instruments for medical use in the nature of genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus and instruments for medical use in the nature of electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations in the nature of medical apparatus for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments for DNA and RNA testing for medical use in the nature of apparatus for DNA and RNA testing for medical purposes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus and instruments for introducing pharmaceutical preparations into the human body in the nature of medical apparatus for introducing pharmaceutical preparations into the human body

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations, namely, pharmaceutical preparations for use in dermatology; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 22, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 22, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 3, 2025 EXRA
SOU EXTENSION 5 GRANTED
Oct 2, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 2, 2025 AITU
SOU TEAS EXTENSION RECEIVED
May 20, 2025 EEXT
SOU EXTENSION 5 FILED
May 19, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 19, 2024 EXRA
SOU EXTENSION 4 GRANTED
Nov 19, 2024 EX4G
SOU EXTENSION 4 FILED
Nov 19, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 19, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 18, 2024 EXRA
SOU EXTENSION 3 GRANTED
May 17, 2024 EX3G
SOU EXTENSION 3 FILED
May 17, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
May 17, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 21, 2023 EXRA
SOU EXTENSION 2 GRANTED
Nov 17, 2023 EX2G
SOU EXTENSION 2 FILED
Nov 17, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 17, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 12, 2023 EXRA
SOU EXTENSION 1 GRANTED
May 10, 2023 EX1G
SOU EXTENSION 1 FILED
May 10, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
May 10, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 22, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Sep 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 18, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 17, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 17, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 17, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 2, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 2, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 2, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 2, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 9, 2022 NWOS
NEW APPLICATION ENTERED
Feb 8, 2022 NWAP